Investigating the role of lipoprotein(a) in aortic stenosis progression
Association of Lipoprotein(a) With Progression of Degenerative Aortic Valve Stenosis: Propensity-matched Study
This study looks at how different levels of lipoprotein(a) might affect the worsening of aortic stenosis in people who have mild to moderate cases of the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 364 (estimated) |
| Sex | All |
| Sponsor | Asan Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06648915 on ClinicalTrials.gov |
What this trial studies
This observational study examines the relationship between lipoprotein(a) levels and the progression of mild to moderate aortic stenosis in a cohort of 1381 patients. Participants are divided into two groups based on their Lp(a) levels: those with levels greater than 70 mg/dL and those with levels less than 30 mg/dL. The study aims to compare the progression of aortic stenosis between these groups while controlling for various risk factors. Additionally, it evaluates how baseline clinical and echocardiographic variables interact with Lp(a) levels in relation to disease progression.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with mild to moderate degenerative aortic stenosis and specific lipoprotein(a) levels.
Not a fit: Patients with bicuspid or rheumatic aortic stenosis, or those with significant cardiac conditions, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of lipoprotein(a) in aortic stenosis progression, potentially guiding future therapeutic strategies.
How similar studies have performed: Previous studies have indicated a correlation between elevated lipoprotein(a) levels and faster progression of aortic stenosis, suggesting that this approach has merit.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Mild to moderate degenerative AVS Aortic peak velocity greater than 2 m/s and smaller than 4 m/s * LP(a) \>70 mg/dL or \<30 mg/dL * Patients must provide written informed consent Exclusion Criteria: * Bicuspid AVS * Rheumatic AVS * Marked bradycardia, tachycardia or 2nd or 3rd degree AV block * LV ejection fraction \< 40% * Hypertrophic or restrictive cardiomyopathy
Where this trial is running
Seoul
- Asan Medical Center — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Duk-Hyun Kang, MD. PhD. — Asan Medical Center
- Study coordinator: Ka-Yoon Kim, MD
- Email: kimgy741@naver.com
- Phone: 82-2-3010-1222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.